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Abstract 
Background: While most studies focus on cardiovascular morbidity following anesthesia and surgery in excessive 
obesity, it is unknown whether these intraoperative cardiovascular alterations also occur in milder forms of adiposity 
without type 2 diabetes and if insulin is a possible treatment to improve intraoperative myocardial performance. In 
this experimental study we investigated whether mild adiposity without metabolic alterations is already associated 
with cardiometabolic dysfunction during anesthesia, mechanical ventilation and surgery and whether these myocar-
dial alterations can be neutralized by intraoperative insulin treatment.
Methods: Mice were fed a western (WD) or control diet (CD) for 4 weeks. After metabolic profiling, mice underwent 
general anesthesia, mechanical ventilation and surgery. Cardiac function was determined with echocardiography and 
left-ventricular pressure–volume analysis. Myocardial perfusion was determined with contrast-enhanced echocardi-
ography. WD-fed mice were subsequently treated with insulin by hyperinsulinemic euglycemic clamping followed by 
the same measurements of cardiac function and perfusion.
Results: Western-type diet feeding led to a 13 % increase in bodyweight, (p < 0.0001) and increased adipose tissue 
mass, without metabolic alterations. Despite this mild phenotype, WD-fed mice had decreased systolic and diastolic 
function (end-systolic elastance was 2.0 ± 0.5 versus 4.1 ± 2.4 mmHg/μL, p = 0.01 and diastolic beta was 0.07 ± 0.03 
versus 0.04 ± 0.01 mmHg/μL, p = 0.02) compared to CD-fed mice. Ventriculo-arterial coupling and myocardial perfu-
sion were decreased by 48 % (p = 0.003) and 43 % (p = 0.03) respectively. Insulin treatment in WD-fed mice improved 
echo-derived systolic function (fractional shortening 42 ± 5 % to 46 ± 3, p = 0.05), likely due to decreased afterload, 
but there was no effect on load-independent measures of systolic function or myocardial perfusion. However, there 
was a trend towards improved diastolic function after insulin treatment (43 % improvement, p = 0.05) in WD-fed 
mice.
Conclusions: Mild adiposity without metabolic alterations already affected cardiac function and perfusion during 
anesthesia, mechanical ventilation and surgery in mice. Intraoperative insulin may be beneficial to reduce afterload 
and enhance intraoperative ventricular relaxation, but not to improve ventricular contractility or myocardial perfusion.
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Background
Adiposity is a characteristic of about 50  % of patients 
undergoing anesthesia and surgery [1], and a risk fac-
tor for the development of cardiovascular complica-
tions in the perioperative setting. On one hand this is 
due to the presence of systolic and diastolic dysfunc-
tion, in part caused by elevated cardiac output, increased 
left-ventricular (LV) wall stress and cardiac hypertrophy 
[2]. On the other hand, increased adiposity is associated 
with decreased coronary flow reserve, which is indica-
tive of impaired myocardial perfusion [3]. Moreover, the 
metabolic and cardiovascular alterations in the over-
weight conditions may influence response to analgesia, 
anesthetics, mechanical ventilation and surgical stress [4, 
5]. Clinical studies focusing on the impact of anesthesia, 
mechanical ventilation and surgery on myocardial func-
tion frequently focus on morbid obesity, while milder 
forms of increased adiposity are neglected as risk factor in 
the perioperative setting. However, even milder forms of 
obesity and the metabolic syndrome are associated with 
a higher incidence of postoperative morbidity, including 
cardiac events [6]. In obese, non-diabetic rats, adrenergic-
mediated hemodynamic effects were distinctly affected by 
the volatile anesthetic isoflurane when compared to non-
obese rats [7]. Moreover, diet-induced obesity in rats is 
associated with systolic dysfunction and myocardial per-
fusion disturbances when compared to lean animals, and 
sevoflurane anesthesia further aggravates this myocardial 
contractile response [8]. Since these animal studies sug-
gest that even non-diabetic adiposity is associated with 
hemodynamic and cardiovascular disturbances in the 
perioperative period, more insight in the pathophysiology 
as well as possible treatment strategies are warranted.
In order to gain insight in the impact of mild adipos-
ity on myocardial function during anesthesia and surgery, 
we investigated whether mild adiposity without meta-
bolic alterations is already associated with intraoperative 
alterations in myocardial function in an experimental 
mouse model. We further hypothesized that mild adipos-
ity is associated with cardiovascular alterations that can 
be restored by perioperative insulin treatment. Insulin 
has positive inotropic effects and it is known that high 
dose insulin improves cardiac function in animals with 
septic and hemorrhagic shock [9, 10] but also in patients 
undergoing cardiac surgery [11].
Methods
Animals
Animal experiments were approved by the Institutional 
Animal Care and Use Committee of the VU University 
(Amsterdam, the Netherlands. Permit number: ANES 
12-04/ANES 13-04), and were conducted following the 
European Convention for the Protection of Vertebrate 
Animals used for Experimental and Other Scientific Pur-
poses and the ARRIVE guidelines on animal research 
[12]. Five week old male C57BL/6J obtained from Charles 
River Laboratories mice were housed in a temperature-
controlled room (20–23  °C; 40–60 % humidity) under a 
12/12 h light/dark cycle starting at 6.00 am. Body weight 
was determined on a weekly basis. After 4 weeks of west-
ern-type diet feeding an oral glucose tolerance test was 
performed and mice subsequently underwent the in vivo 
protocol consisting of left ventricular (LV) pressure–vol-
ume measurements and (contrast-) echocardiography 
under anesthesia. At the end of the experiment, mice 
were euthanized by heart excision under anesthesia.
Adiposity model and metabolic profiling
Mice were randomized into a group fed a western-type 
diet (D12079B, Research Diets New Brunswick, NJ) con-
sisting of 17 % kcal protein, 43 % kcal carbohydrates and 
41 % kcal fat, ad libitum for 4  weeks. The control group 
was fed a normal chow diet (Teklad 2016, Harlan, Horst, 
the Netherlands) with 16 % kcal protein, 4 % kcal fat and 
80 % kcal carbohydrates for 4  weeks.
An oral glucose tolerance test (OGTT) was performed 
after 4  weeks of diet exposure. After overnight fasting, 
conscious mice received a bolus of glucose (2  g/kg) via 
oral gavage. Blood was drawn from a tail-cut immediately 
before glucose challenge and at 15, 30, 60, 90 and 120 min 
thereafter using a Precision Xceed Blood Glucose moni-
toring system (MediSense, UK). The area under the blood 
glucose curve (AUC) was used to compare glucose toler-
ance between western-type and control diet-fed mice.
In mice that had only undergone baseline measure-
ments and no insulin treatment, blood was drawn from 
the right ventricle of the heart and plasma concentrations 
of fasting insulin, free fatty acids and triglycerides were 
measured using commercial ELISA and enzymatic meas-
urement kits according to the manufacturer (LINCO 
research, St. Charles, MO; WAKO NEFA-C, Wako Pure 
Chemical Industries, Osaka, Japan).
Anesthesia and mechanical ventilation
After 4  weeks of diet exposure, anesthesia was induced 
with fentanyl 0.5 mg/kg, midazolam 9.4 mg/kg and ace-
promazine 9.4 mg/kg injected intraperitoneally. Anesthe-
sia was maintained by continuous intravenous infusion of 
fentanyl 0.1  mg/kg/h, midazolam 2.3  mg/kg/h and ace-
promazine 2.3 mg/kg/h via a 26G cannula in the tail vein. 
The trachea was intubated and the lungs were mechani-
cally ventilated (maximal pressure 12–14 cm H2O; posi-
tive end-expiratory pressure, 2–4  cm H2O; respiratory 
rate 150 breaths/min) with oxygen-enriched air (40  % 
O2/60 % N2). Body temperature was maintained at 37 °C 
using a body-temperature controlled heating pad.
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Surgery and monitoring
A catheter was placed in the right jugular vein for infu-
sion of contrast agent, insulin and/or glucose. The left 
carotid artery was cannulated for measurements of arte-
rial blood pressure (Safedraw Transducer Blood Sam-
pling Set, Argon Medical Devices, Texas, USA). Arterial 
blood pressure, ECG, heart rate and temperature were 
continuously recorded using PowerLab software (Power-
Lab 8/35, Chart 8.0; ADInstruments Pty, Ltd., Castle Hill, 
Australia).
Experimental protocol
After induction of anesthesia and cannulation of veins 
and arteries, mice underwent different experimental pro-
tocols, which are depicted in Fig. 1. (Contrast-enhanced) 
echocardiography measurements at baseline and during 
insulin treatment were paired (group A). However, pres-
sure–volume loop measurements could not be paired 
due to the invasive nature of insertion of the Millar cath-
eter in the LV (group B, C).
(Contrast‑enhanced) echocardiography
(Contrast-enhanced) echocardiography was performed 
using a Siemens (ACUSON, Sequoia 512) device equipped 
with a 14 MHz linear array transducer as described previ-
ously [8, 13]. Before infusion of contrast agent, contractile 
function was determined by visualizing the LV in short 
axis midpapillary view, and left ventricular end-systolic 
(ESD) and end-diastolic (EDD) diameters were deter-
mined in M-mode. LV systolic function is represented 
by fractional shortening (FS) which was calculated by 
the following equation: FS  =  (EDD  −  ESD)/EDD·100). 
All parameters were averaged over at least three cardiac 
contractile cycles. A typical example of echocardiography 
windows in control versus western diet-fed mice is shown 
in Fig. 2, upper part of panels a and b.
Contrast-echocardiography was performed as previ-
ously described [8, 13, 14]. Briefly, perfluorbutane filled 
microbubbles were continuously infused into the jugular 
vein and visualized in midpapillary short-axis views of 
the LV. After two minutes of microbubble infusion, per-
fusion recordings were taken with low acoustic power 
(mechanical index [MI] 0.19) for microbubble detec-
tion with a dynamic range of 50 dB, followed by a burst 
of high acoustic power (MI 1.8) for complete contrast 
destruction. Subsequently, on average 80 cardiac cycles 
of low MI images were acquired to allow contrast replen-
ishment in the myocardium. All data were stored for 
offline analysis.
Custom-designed software was used for analysis of the 
estimate of myocardial perfusion (Matlab, 7.10, R2010A, 
MathWorks Inc. MA, USA) [14]. For each cardiac cycle, 
regions of interest were drawn in the end-systolic frame 
in the short axis view of the LV myocardium. Signal 
intensities from the frames after microbubble destruc-
tion were corrected for background noise by subtracting 
the signal intensity of the first frame after microbub-
ble destruction (Y0). These intensities were then fitted 
[Y = Y0 + (A−Y0)·(1−exp(−ß·x))] for calculation of micro-
vascular blood volume A and the microvascular fill-
ing velocity ß, which corresponds to the capillary blood 
exchange rate. The estimate of myocardial perfusion was 
calculated as the product of A and ß.
Pressure–volume loops
After induction of anesthesia a subcostal thoracotomy 
was performed and a pressure–volume Millar cath-
eter (SPR 869, Millar Instruments, Houston, TX) was 
inserted in the LV via the apex. The Millar catheter 
Fig. 1 Experimental protocol. After induction of anesthesia and 
cannulation of vessels mice underwent contrast-enhanced echo-
cardiography at baseline and after insulin treatment (group A), or 
pressure–volume loop analysis at baseline (group B) and after insulin 
treatment (group C)
Fig. 2 Typical examples of echocardiography and pressure–volume 
loops measurements in control (a) and western diet-fed (b) mice. 
Echocardiography windows are short axis midpapillary views which 
where used for estimation of fractional shortening, and demon-
strated pressure volume loops were used for estimation of end-
systolic (striped line) and end-diastolic (dotted line) pressure–volume 
relation estimations and related parameters
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continuously measures pressure and volume in the LV, 
and the volume signal was calibrated with stroke volume 
estimations that were obtained with echocardiography in 
the closed-chest situation. A ligature was placed under 
the inferior vena cava for transient preload reductions. 
Pressure–volume loops were measured in three series 
with vena cava occlusion-induced preload reduction. In 
a different group of mice, the same measurements were 
performed after hyperinsulinemic euglycemic clamping. 
Analysis of pressure volume loops was performed using 
PowerLab software (PowerLab 8/35, Chart  8.0; ADIn-
struments Pty, Ltd., Castle Hill, Australia). From steady 
state measurements, LV mean and end-systolic pres-
sures as well as arterial elastance (Ea), a measure for left 
ventricular afterload, were determined. From vena cava 
occlusion data, end-systolic elastance (Ees) was deter-
mined as the slope of the end-systolic pressure–volume 
relationship, a load-independent measure for cardiac 
contractility. The slope of the end-diastolic pressure–
volume relationship, Beta, was determined, which is 
considered a load-independent determinant of diastolic 
function. The ratio Ees/Ea was determined as an estimate 
of ventriculo-arterial coupling, which describes adapta-
tion of the LV in relation to the vasculature [15]. Typi-
cal examples of pressure–volume loops measurements 
during vena cava occlusion and related end-systolic and 
end-diastolic pressure–volume relations in control ver-
sus western-diet fed mice are shown in Fig.  2, the bot-
tom of panels a and b.
Insulin treatment
For insulin treatment with maintenance of euglycemic 
conditions, a hyperinsulinemic clamp was performed as 
described [16] after overnight fasting and under anesthe-
sia. After determination of baseline glucose level a bolus 
of 100  mU/kg insulin was administered intravenously 
over 2  min followed by continuous infusion of insulin 
at a rate of 3 mU/kg/min for 60 min. Blood glucose lev-
els were determined at intervals of 5  min and glucose 
infusion (20 % glucose diluted in NaCl) was adjusted to 
maintain euglycemia. After 60 min a steady state of eug-
lycemia was achieved and mice were otherwise excluded 
from analysis.
Data analysis
All data are presented as mean and standard deviation 
(SD). Statistical differences between the western-type 
diet and the control group were tested using a Student t 
test or two-way ANOVA for variables with multiple time 
points. The difference between insulin-stimulated condi-
tions and the baseline condition in the obese group were 
tested with paired or Student t tests. A p < 0.05 was con-
sidered as statistically significant.
Results
Mild adiposity model
Characteristics of mice fed a control or western diet for 
4 weeks are shown in Table 1. Western diet (WD) feeding 
led to an increase in caloric intake of almost 20 % com-
pared to chow diet (p < 0.0001), which resulted in 13 % 
higher bodyweight (p < 0.0001) compared to controls and 
higher heart- and fatpad weights. There was no hyper-
glycemia, hyperinsulinemia or hyperlipidemia as deter-
mined under fasting conditions. Furthermore, an oral 
glucose tolerance test and hyperinsulinemic euglycemic 
clamp revealed the absence of glucose intolerance (area 
under the curve was 1823 ± 156 versus 1549 ± 68 in con-
trol mice, p  =  0.13) and whole body insulin resistance 
(glucose infusion rate during hyperinsulinemic clamp 
was 24 ± 3 in WD-fed mice versus 25 ± 2 mg/min/kg in 
control mice, p = 0.73).
Mild adiposity does not alter hemodynamics
Hemodynamics as measured under stable, anesthetized 
conditions are described in Table  2. Under anesthesia, 
there was no difference in mean arterial pressure between 
WD- and CD-fed mice (61 ± 19 versus 66 ± 17 mmHg 
Table 1 Metabolic characteristics of  control and  WD-fed 
mice
Metabolic characteristics of control and WD-fed mice. AUC area under the curve. 
Data are presented as mean ± SD and n = 8–12 per group. Data were analyzed 
using a Student’s t test for between-group comparisons and 2-way ANOVA with 
repeated measurements for the oral glucose tolerance test (OGTT)
Control WD‑fed p value
Body weight (g) 23.8 ± 0.8 27.0 ± 1.2 <0.0001*
Tibia length (mm) 17.2 ± 0.4 17.1 ± 0.4 0.66
Caloric intake (g/kg/week) 3.2 ± 0.1 3.8 ± 0.2 <0.0001*
Non-fasting blood glucose 
(mmol/L)
11.5 ± 1.9 11.8 ± 1.8 0.47
Fasting blood glucose (mmol/L) 6.2 ± 0.8 5.7 ± 0.6 0.18
Heart weight (mg) 103.1 ± 4.0 127.4 ± 16.0 0.01*
Left ventricular weight (mg) 79.5 ± 4.1 102.0 ± 15.8 0.001*
Right ventricular weight (mg) 19.1 ± 2.7 20.8 ± 4.0 0.34
Epididymal adipose tissue (mg) 184.3 ± 32.3 308.0 ± 119.1 0.01*
Perirenal adipose tissue (mg) 50.8 ± 10.2 84.5 ± 48.1 0.07
Epicardial adipose tissue (mg) 2.4 ± 1.0 7.2 ± 6.3 0.05
Plasma insulin (ng/mL) 2.71 ± 1.31 3.16 ± 1.06 0.85
Plasma triglycerides (ng/mL) 0.48 ± 0.05 0.55 ± 0.07 0.40
Plasma free fatty acids  
(nmol/mL)
0.09 ± 0.02 0.09 ± 0.02 0.51
Oral glucose tolerance test AUC 1549 ± 68 1823 ± 156 0.13
Hyperinsulinemic euglycemic clamp
 Steady state blood glucose 
(mmoll/L)
5.4 ± 0.2 5.6 ± 0.2 0.42
 Glucose infusion rate  
(mg/min/kg)
25 ± 2.2 24 ± 2.8 0.73
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in control mice, p = 0.34). Furthermore, although stroke 
volume showed a trend towards lower values in WD-fed 
mice (36 ± 2 versus 45 ± 4 μL in control mice p = 0.07), 
cardiac output was unaltered compared to controls.
Mild adiposity impairs cardiac function and perfusion
Cardiac function and perfusion parameters are described 
in Table  3. WD-feeding resulted in decreased systolic 
function as determined with echocardiography (frac-
tional shortening 43 ± 6 % versus 56 ± 8 %, p ≤ 0.0001) 
as well as an almost 50  % decrease in pressure–volume 
loop-derived end-systolic elastance (Ees was 2.0  ±  0.5 
versus 4.1 ± 2.4 mmHg/μL, p = 0.01) compared to CD-
feeding. Afterload (Ea) did not differ between groups. 
Ventriculo-arterial coupling (Ees/Ea) was diminished in 
WD-fed mice compared to controls (coupling ratio was 
1.3 ±  0.6 versus 2.5 ±  1.4 in control mice, p =  0.003). 
Furthermore, WD-feeding increased diastolic Beta 
(0.07  ±  0.03 versus 0.04  ±  0.01  mmHg/μL, p  =  0.02) 
compared to controls, which implies a stiffer ventricle. 
Myocardial perfusion was decreased by 43 % in WD-fed 
mice compared to CD-fed mice (p = 0.03).
Insulin treatment improves diastolic function in mildly 
adipose mice
Hemodynamics and cardiac responses to insulin treat-
ment in WD-fed mice are described in Table 4 and visu-
alized in Fig. 3. After 1 h of insulin treatment, euglycemia 
was maintained at 5.6  ±  0.17  mmol/L. Mean arterial 
blood pressure and cardiac output remained unaltered 
during insulin treatment, despite a decrease in heart 
rate. However, insulin decreased end-systolic pressure 
(61 ± 19 mmHg to 43 ± 8 mmHg, p = 0.03), and there 
was a trend towards lower afterload (Ea decreased from 
1.8 ± 0.9 to 1.2 ± 0.4 mmHg/μL, p = 0.07) during insulin 
treatment. While systolic echocardiographic parameters 
improved slightly in WD-fed mice during insulin treat-
ment (fractional shortening increased from 42 ± 5 % to 
46 ± 3, p = 0.05), there was no improvement in end-sys-
tolic elastance (Ees was 1.6 ± 0.3 versus 2.0 ± 0.1 mmHg/
μL at baseline) nor in ventriculo-arterial coupling. Fur-
thermore, there was a trend towards decreased Beta 
during insulin treatment (−43  % from 0.07  ±  0.01 to 
0.04  ±  0.01  mmHg/μL p  =  0.05), indicating improved 
diastolic function. Finally, myocardial perfusion was 
unaffected by insulin treatment in WD-fed mice.
Discussion
In this study we demonstrated that a mild, early stage 
of diet-induced adiposity is already associated with 
decreased systolic and diastolic function, diminished 
ventriculo-arterial coupling and impaired myocardial 
perfusion during anesthesia, mechanical ventilation 
and surgery in mice. In this phenotype, intraoperative 
insulin treatment improved echo-derived systolic func-
tion, decreased afterload and showed a trend towards 
improved diastolic function. However, there was no 
effect on load-independent measurements of systolic 
Table 2 Baseline hemodynamics for  control and  WD-fed 
mice
Data are presented as mean ± SD and n = 6–12 per group. Student t test, 
* p < 0.05
Control WD‑fed p value
Mean arterial pressure (mmHg) 66 ± 17 61 ± 19 0.34
Heart rate (BPM) 604 ± 120 670 ± 65 0.18
Stroke volume (μL) 45 ± 11 36 ± 7 0.07
Cardiac output (mL/min) 26.8 ± 8.4 24.4 ± 3.6 0.46
End-systolic pressure (mmHg) 67 ± 16 61 ± 19 0.46
Table 3 Myocardial function and  perfusion parameters 
in WD-fed mice compared to controls
Data are presented as mean ± SD and n = 6–12 per group. Student t test, 
* p < 0.05
Control WD‑fed p value
Fractional shortening (%) 56 ± 8 43 ± 6 <0.0001*
End-systolic elastance  
(Ees; mmHg/μL)
4.1 ± 2.4 2.0 ± 0.5 0.01*
Arterial elastance  
(Ea; afterload; mmHg/μL)
1.6 ± 0.4 1.8 ± 0.9 0.51
Ventriculo-arterial coupling 
(Ees/Ea ratio)
2.5 ± 1.4 1.3 ± 0.6 0.003*
Beta (diastolic stiffness; 
mmHg/μL)
0.04 ± 0.01 0.07 ± 0.03* 0.02*
Myocardial perfusion
 Microvascular flow velocity 
β (sec−1)
0.49 ± 0.20 0.59 ± 0.30 0.24
 Microvascular blood volume 
A (A.U.)
0.014 ± 0.006 0.008 ± 0.005* 0.006*
 Estimate of myocardial 
perfusion (A × β)
0.007 ± 0.005 0.004 ± 0.003* 0.03*
Table 4 Hemodynamic response during  insulin treatment 
in WD-fed animals
Data are presented as mean ± SD and n = 7–10 per group. Student t test, 
* p < 0.05
Baseline After insulin 
treatment
p value
Mean arterial pressure 
(mmHg)
61 ± 19 63 ± 12 0.91
Heart rate (BPM) 669 ± 65 593 ± 73 0.045*
Stroke volume (μL) 36 ± 7 39 ± 10 0.45
Cardiac output (mL/min) 24.4 ± 3.6 23.1 ± 6.4 0.58
End-systolic pressure 
(mmHg)
61 ± 19 43 ± 18 0.03*
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function or myocardial perfusion. These combined find-
ings suggest mild adiposity already compromises cardiac 
function during anesthetized and mechanically ventilated 
conditions, and that intraoperative insulin treatment 
may be applied to positively modulate loading conditions 
and ventricular relaxation, but not to influence cardiac 
contractility.
Mild obesity is associated with intraoperative myocardial 
depression
In the present study we timed diet exposure to induce 
an early stage of adiposity without insulin resistance, so 
that the effect of early overweight conditions without 
confounding metabolic alterations could be studied. We 
demonstrated that intraoperative myocardial depression 
is already present in this early stage. Therefore, mildly 
adipose patients may be at increased risk for periopera-
tive cardiac alterations, even when presenting in the early 
stage without metabolic alterations.
In literature, conflicting results have been reported 
regarding the effect of diet-induced adiposity on systolic 
function. Some report decreased [8, 13, 17, 18] others 
unchanged [19] or even improved [20] systolic function. 
Studies on cardiac function in obesity in the periop-
erative setting are rare, but have shown additional car-
diodepressive effects of sevoflurane in diet-induced obese 
rats [8]. In our mild phenotype we found impaired frac-
tional shortening but also load-independent end-systolic 
elastance, indicating that this is a true contractility effect. 
Decreased ventriculo-arterial coupling furthermore indi-
cates inadequate adaptation of the heart to the vascu-
lature. Importantly, exposure to general anesthesia and 
mechanical ventilation in combination with surgical stress 
in our study, may have exacerbated subclinical systolic 
dysfunction that would otherwise remain undetected.
Diastolic dysfunction is a consistent finding in diet-
induced adiposity, and is the predominant cardiac fea-
ture in earlier stages of human obesity [2]. The increased 
Fig. 3 Cardiac function and perfusion response to insulin treatment in WD-fed mice. Cardiac systolic (a), and diastolic (b) function and perfusion  
(c) responses to insulin treatment. Data are mean ± SD and n = 7–10 per group. Paired t test for perfusion-related parameters, Student t test for 
other parameters, *p < 0.05
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slope of the end-diastolic pressure–volume relation in 
our study indicates increased ventricular stiffness, which 
is a finding consistent with several other animal stud-
ies on diet-induced adiposity [17, 18], although to our 
knowledge this has not been described in this early stage 
before.
Cardiac function relies on adequate myocardial perfu-
sion [21], for which microvascular function and respon-
siveness are important determinants. In this study we 
demonstrated impaired myocardial perfusion in mild adi-
posity, indicating that myocardial vascular dysfunction is 
an early phenomenon in diet-induced adiposity. Impaired 
vasodilatory responses have earlier been demonstrated 
in isolated hearts of obese mice fed a high fat diet for 
8 weeks [22]. Moreover, rats exposed to high fat diet for 
6  weeks had impaired microvascular responsiveness to 
adenosine administration [19]. In overweight, obese [3, 
23] and morbidly obese [23, 24] subjects, endothelium-
dependent myocardial perfusion responses to cold pres-
sure test as well as the response to dipyridamole were 
blunted. These findings indicate impaired microvascular 
responsiveness, and disturbances in microvascular func-
tion have been related to hyperglycemia, dyslipidemia 
and insulin resistance [25, 26]. Interestingly, in this study 
none of these were characteristics of our model, indicat-
ing that impairments of myocardial perfusion and func-
tion occur independently from metabolic defects in early 
stages of increased adiposity.
Effect of intraoperative insulin treatment
The increasing prevalence of overweight and obese 
patients that undergo surgery under anesthesia and the 
myocardial depression demonstrated in the described 
mouse model warrant treatment strategies to optimize 
perioperative cardiac function. Insulin has been shown 
to improve cardiac function in the setting of acute myo-
cardial infarction, ischemia and reperfusion injury, sep-
sis and hemorrhagic shock [9, 10, 27, 28]. In addition, 
perioperative insulin treatment was beneficial in car-
diothoracic surgery [11, 29, 30] although another study 
showed no benefit in cardiothoracic surgery [31]. Up to 
now, no studies have investigated how insulin influences 
perioperative myocardial depression in overweight and 
obesity, but we hypothesized a beneficial effect. While 
most studies have used glucose-insulin-potassium (GIK) 
as insulin treatment, in this study we used hyperinsu-
linemic euglycemic clamping for this purpose because 
maintenance of euglycemia eliminates the possible 
effects of hypo- and hyperglycemia on myocardial perfu-
sion and function itself [32]. Furthermore, insulin itself 
and not glucose or potassium was shown to be the factor 
responsible for the beneficial effects of GIK in a previous 
study [33].
In the present study, insulin treatment improved intra-
operative fractional shortening, but not load-independ-
ent end-systolic elastance in mildly adipose mice. In 
combination with decreased afterload and end-systolic 
pressure during hyperinsulinemia, this effect is most 
likely due to peripheral vasodilation, which is in concord-
ance with previous findings [29, 34, 35]. Most studies 
that demonstrated a benefit of insulin on perioperative 
cardiac function have used load-dependent parameters 
such as cardiac index [35–37], while others who studied 
load-independent measures such as myocardial strain, 
showed no effect [31]. This supports our findings that 
insulin mainly affects loading conditions, but not load-
independent measurements of contractility. In this study, 
there was a trend towards improved diastolic function 
after insulin treatment, which is in agreement with ear-
lier studies in lean animals [38]. We did however not 
observe an increase in myocardial perfusion upon insulin 
treatment, while insulin is known as a vasodilating agent 
in the myocardium [39]. Impaired vasodilation to insulin 
has however been demonstrated in other tissues in obe-
sity, and may be consistent with the presence of micro-
vascular dysfunction [16].
Taken together, these results suggest that intraopera-
tive insulin treatment does not improve systolic function 
or myocardial perfusion, but decreases afterload and may 
improve ventricular relaxation when administered intra-
operatively to mildly adipose mice with cardiodepres-
sion. While decreased systemic vascular resistance and 
afterload may reduce cardiac work load, it may also cause 
hypotension which could negatively affect tissue perfu-
sion. However, we did not observe a significant effect on 
blood pressure and myocardial perfusion in this study. 
Although we observed no effects on systolic function, 
the trend towards a beneficial effect on diastolic function 
that we observed may on itself be relevant in the perio-
perative period. Diastolic dysfunction is an important 
risk factor in the perioperative period, as hemodynamic 
changes such as arrhythmias and tachycardia may affect 
diastolic filling, and existing diastolic dysfunction can 
acutely decompensate in the perioperative period [40].
Conclusions
In conclusion, mild adiposity is already associated with 
intraoperative myocardial depression in mice. Intraop-
erative insulin treatment improved echo-derived sys-
tolic function, decreased afterload and showed a trend 
towards improved diastolic function, but not load-inde-
pendent measurements of systolic function or myocar-
dial perfusion. These combined findings suggest that the 
early stage of adiposity without metabolic alterations 
already compromises cardiac function during anesthe-
tized and mechanically ventilated conditions, and that 
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intraoperative insulin treatment may be applied to modu-
late loading conditions and ventricular relaxation, but 
not to influence cardiac contractility.
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